KUBIX
Gene expression diagnosis for digestive system cancers.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
$1.1m | Late VC | ||
| Total Funding | 000k | ||
Related Content
KUBIX Inc. is a biotechnology company that originated as a spin-off from Kanazawa University in August 2004. The company's president is Hiroshi Tanno. With a core philosophy of "From Research to Clinical," KUBIX focuses on the practical application of advanced medical research, particularly in gene expression analysis for the early detection of diseases.
The company's primary business revolves around contract testing services and the development, manufacturing, and sales of reagent kits. Its main offering is the "Digestive System Cancer Microarray Blood Test," which analyzes blood-derived RNA to determine the presence of gastrointestinal cancers like stomach, colon, pancreatic, and biliary tract cancer. Another key service is "AlcoRisk," a test that assesses the risk of developing esophageal and head and neck cancers by analyzing alcohol-metabolizing enzyme gene polymorphisms combined with a questionnaire. KUBIX also provides Next-Generation Sequencing (NGS) analysis for hereditary dyslipidemia and an mRNA blood test for pancreatic cancer. Their services extend to contract research, including nucleic acid extraction, real-time PCR, and microarray gene expression analysis for medical and research institutions.
KUBIX operates in the MedTech and biotechnology sectors, serving medical institutions and researchers. The business model is centered on providing specialized testing services and selling diagnostic kits. The company has received several awards, including the "Japan Venture Society President's Award" in 2014 and the "Minister of Economy, Trade and Industry Award" at the 13th Industry-Academia-Government Collaboration Commendation in 2015. In December 2018, the company relocated to a new facility in Hakusan City, Ishikawa, equipped with a clean room for manufacturing in-vitro diagnostic reagents.
Keywords: gene expression analysis, cancer diagnostics, microarray blood test, biotechnology, MedTech, genetic testing, digestive cancer, RNA analysis, PCR services, NGS analysis, disease risk assessment, in-vitro diagnostics, clinical research support, nucleic acid extraction, Kanazawa University venture